Day: January 14, 2026

Karri AlameriOmaSp:n toimitusjohtaja Karri AlameriJaakko OssaOmaSp:n hallituksen puheenjohtaja Jaakko OssaOmaSp konttoriOmaSp konttori TurkuOMA SAVINGS BANK PLC STOCK EXCHANGE RELEASE, 14 JANUARY 2026 AT 16.20 P.M. EET, OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE Oma Savings Bank Plc’s Growth Strategy for 2026–2029 The Board of Directors of Oma Savings Bank Plc (“OmaSp” or the “Company”) has approved the Company’s strategy and financial targets for the 2026–2029 period. The goal of the strategy is to grow the Company responsibly and profitably, utilising personalised service as a competitive advantage. OmaSp focuses on retail customers and the SME sector. New financial targets for 2026–2029:Comparable ROE: over 14% Comparable cost-to-income ratio: below 50% Annual growth in fee and commission...

Access the segment here SOUTH SAN FRANCISCO, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it participated in a Virtual Investor CEO Connect Segment. As part of the segment, Timothy Lu, MD, PhD, CEO of Senti, discussed its recent news release announcing that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202, the Company’s potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy, that is currently in development for the treatment of relapsed/refractory hematologic malignancies, including...

Company Achieves Record ARR in December, Representing a 300% Increase Over the Past 12 Months Fort Lauderdale, FL, Jan. 14, 2026 (GLOBE NEWSWIRE) — Algorhythm Holdings, Inc. (“Algorhythm”) (NASDAQ: RIME) – a leading AI technology company, announced today that achieved an annualized revenue run rate (“ARR”) of $9.7 million during December 2025, representing a 300% increase over the $2.5 million ARR that the company reached at the end of 2024. During 2025, SemiCab achieved five new contract wins with some of the largest multinational fast moving consumer goods companies (FMCGs) in India and was awarded seven contract expansions for increased lanes and trip volume. SemiCab is taking an increasing share of what is an enormous total addressable market.Current Clients & Market Coverage: In the Indian metropolitan regions SemiCab...

HERNDON, Va., Jan. 14, 2026 (GLOBE NEWSWIRE) — Navient (Nasdaq: NAVI) will host an audio webcast to review its 2025 fourth quarter and year-end financial results on Wednesday, Jan. 28, 2026, at 8:00 a.m. Eastern Time. The webcast will be available on Navient.com/investors; a replay of the webcast will be available on the site. The results and presentations slides will be available the same day by 7:00 a.m. on Navient.com/investors. In addition to being available on the company’s investor website, the results will be filed with the SEC on a Form 8-K available at SEC.gov. About NavientNavient (Nasdaq: NAVI) creates long-term value for customers and investors with responsible lending, flexible refinancing, trusted servicing oversight, and decades of education finance and portfolio management expertise. Through our Earnest business,...

Las Vegas, NV, Jan. 14, 2026 (GLOBE NEWSWIRE) — Jet.AI Inc. (“Jet.AI” or the “Company”) (Nasdaq: JTAI), an emerging provider of high-performance GPU infrastructure and AI cloud services, today announced that the parties have extended the outside date of the merger agreement between flyExclusive, Inc. (NYSE American: FLYX) (“flyExclusive”) and Jet.AI to April 30th, 2026, with closing expected in the first quarter of 2026. “We’re excited about the deal and remain firmly committed,” said Jet.AI Founder and Executive Chairman Mike Winston.” flyExclusive’s Founder and Chief Executive Officer, Jim Segrave added: “We remain enthusiastically committed to the deal.” About Jet.AI Jet.AI Inc. is a technology-driven company focused on deploying artificial intelligence tools and infrastructure to enhance...

First data on blood-based mRNA signature for pancreatic ductal adenocarcinoma (PDAC) detection and intraductal papillary mucinous neoplasms (IPMN) differentiation to be presented in San Diego BERKELEY, Calif. and , Jan. 14, 2026 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, is excited to announce its participation in the upcoming American Association for Cancer Research (AACR) 2026 Annual Meeting. This prestigious conference will be held April 17 to 22, 2026, in San Diego, California. Organized by the American Association for Cancer Research, this premier event gathers scientists, clinicians, and industry leaders from around the world to share groundbreaking cancer research and explore new approaches in oncology. At AACR the Company will...

Special closed-ended type private equity investment company INVL Technology, legal entity code 300893533, the registered address Gyneju str. 14 Vilnius, Lithuania (hereinafter – “the Company” or “ INVL Technology”), informs that on the initiative and decision of the management company UAB „INVL Asset Management“ (hereinafter – “the Management Company“), the Extraordinary General Shareholders Meeting (hereinafter – “the Meeting”) is to be held on 5 February 2026. The place of the Meeting: the office of the Company, the address Gyneju str. 14, Vilnius. The Meeting will start at 9:00 a.m. (registration starts at 8:30 a.m.).  The accounting day of the Meeting is 29 January 2026 (the persons who are shareholders of the Company at the end of the accounting day of the Meeting or their authorised representatives, or the persons with whom shareholders...

INVL Technology (hereinafter – “the Company”) announces its decision to call an extraordinary general meeting of shareholders at which draft resolutions on extending the Company’s term of operations and related amendments to its Articles of Association will be submitted for consideration. The Company’s current Articles of Association set out that the Company’s term of operations shall continue until 14 July 2026, with the possibility of extending that term for a period of up to 2 (two) years. It will be proposed to the extraordinary general meeting of shareholders that this possibility envisaged in the Articles of Association be made use of and that the Company’s term of operations be extended until 14 July 2028. In the assessment of the Company, some of the portfolio companies still have significant growth potential, thus extending the...

SUNNYVALE, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) — Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced certain unaudited preliminary fourth quarter and full year 2025 financial results ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. Financial and Operational HighlightsFourth quarter 2025 worldwide procedures (da Vinci and Ion combined) grew approximately 18% compared with the fourth quarter of 2024. Da Vinci procedures grew approximately 17% and Ion procedures grew approximately 44%. Average da Vinci system utilization increased 4% in the fourth quarter of 2025 as compared with the fourth quarter of 2024, primarily driven by adoption of da Vinci 5 in the U.S. and continued...

ORION CORPORATION STOCK EXCHANGE RELEASE 14 JANUARY 2026 at 16:00 EET         Orion updates time estimate for the potential related to the annual Nubeqa® net sales recorded by Orion  As the company announced earlier today on 14 January 2026, the Nubeqa® product has become Orion’s largest product by far, and its financial significance for the company will increase further. For this reason, Orion decided to provide an estimate of the net sales potential of Nubeqa®. As noted earlier, based on scenario planning with partner Bayer, Orion estimates that the annual Nubeqa net sales recorded by the company (tablet sales to Bayer + royalties) has the potential to exceed EUR 1 billion in the future. It is difficult to estimate the timing for the realization of this net sales potential, as it is influenced by various changing conditions...